금속 이중층 수산화물을 포함하는 생체 주사제용 약물 담체
    11.
    发明授权
    금속 이중층 수산화물을 포함하는 생체 주사제용 약물 담체 有权
    包含层状双氢氧化物的可注射药物载体

    公开(公告)号:KR101207553B1

    公开(公告)日:2012-12-03

    申请号:KR1020050047235

    申请日:2005-06-02

    Applicant: (주)씨앤팜

    CPC classification number: A61K9/0019 A61K9/143 A61K47/02

    Abstract: 본발명은무독성금속이중층수산화물및 약제학적으로허용가능한첨가제를포함하는주사제용약물담체에관한것이다. 보다구체적으로, 본발명은다양한조성을갖는금속이중층수산화물을합성하는단계, 생체파괴를일으키지않는수준으로금속이중층수산화물의크기와입형을조절하는단계, 금속이중층수산화물을용매에분산시켜생체에주입하는단계를포함한다. 본발명에따르면, 생물체의혈관에영향을주지않는나노크기의금속이중층수산화물을합성할수 있으며, 이렇게합성된금속이중층수산화물은 400mg/kg 까지의투여량에도생체에악영향을끼치지않으면서, 특정약물의전달효율을높일수 있는약물전달체시스템을확립할수 있다.

    개선된 특성을 갖는 혼성물질 및 그 제조 방법
    13.
    发明公开
    개선된 특성을 갖는 혼성물질 및 그 제조 방법 有权
    具有改进性能的混合材料及其制备方法

    公开(公告)号:KR1020080009653A

    公开(公告)日:2008-01-29

    申请号:KR1020070073442

    申请日:2007-07-23

    Applicant: (주)씨앤팜

    Abstract: A mixture material in which a complex of an active ingredient-micelle is hybridized into pores of a meso porous inorganic structure is provided to make a drug be stable at light and heat and show the controlled releasing property, thereby lowering the toxicity of the drug itself and also increasing the transmission efficiency of the drug into cells. A method for preparing the same is provided to simply obtain the mixture material with only two steps. A mixture material is characterized in that a complex of an active ingredient-micelle in which the active ingredient is supported on a micelle of a biocompatible copolymeric polymer surfactant is hybridized with pores of a meso porous inorganic structure, wherein the surfactant is a compound of EOnPOmEOn (n is an integer from 20-106 and m is an integer from 40-100), the meso porous inorganic structure is made of SiO2 or TiO2, and the active ingredient is a water-insoluble drug. A method for preparing the mixture material comprises the steps of: (a) reacting an aqueous solution of a mixture consisting of an active ingredient, a biocompatible copolymeric polymer surfactant with the concentration of more than the critical micelle formation, and an inorganic precursor at a temperature of 25-40 deg.C to form a complex of an active ingredient-micelle in which the active ingredient is supported on the micelle of the surfactant; and (b) subjecting the complex formed aqueous solution to hydrothermal reaction at a temperature of 80-130 deg.C to prepare an organic-inorganic complex.

    Abstract translation: 提供其中将活性成分胶束的复合物与中孔多孔无机结构的孔杂交的混合材料,以使药物在光和热下稳定并显示出控制释放性质,从而降低药物本身的毒性 并且还将药物的传播效率提高到细胞中。 提供了制备该方法的方法以简单地仅获得两步的混合材料。 混合材料的特征在于将活性成分 - 胶束的复合物与活性成分负载在生物相容性共聚物表面活性剂的胶束上,与内消旋多孔无机结构的孔杂交,其中表面活性剂是EOnPOmOn的化合物 (n为20〜106的整数,m为40〜100的整数),中空多孔无机结构由SiO 2或TiO 2构成,活性成分为水不溶性药物。 一种制备该混合物材料的方法包括以下步骤:(a)使活性成分,生物相容性共聚物表面活性剂的浓度超过临界胶束形成的混合物的水溶液与无机前体反应, 温度为25-40℃,形成活性成分胶束的复合物,其中活性成分负载在表面活性剂的胶束上; 和(b)使复合物形成的水溶液在80-130℃的温度下进行水热反应以制备有机 - 无机络合物。

    금속 이중층 수산화물을 포함하는 생체 주사제용 약물 담체
    14.
    发明公开
    금속 이중층 수산화물을 포함하는 생체 주사제용 약물 담체 有权
    包含层状双氢氧化物的注射式药物载体

    公开(公告)号:KR1020060125280A

    公开(公告)日:2006-12-06

    申请号:KR1020050047235

    申请日:2005-06-02

    Applicant: (주)씨앤팜

    CPC classification number: A61K9/0019 A61K9/143 A61K47/02

    Abstract: An injectable drug carrier comprising double-layered hydroxide is provided to remove a destruction risk of blood vessel by the double-layered hydroxide, and deliver an effective drug into the human body without toxicity and side effects. The injectable drug carrier comprises the nontoxic double-layered hydroxide and a pharmaceutically acceptable additive, wherein the particle size of the double layered hydroxide is 100-300 nm; and drug is MTX(methotrexate). The method for preparing the injectable drug carrier comprises the steps of: titrating divalent or trivalent metal salt solution with base solution to synthesize the double-layered hydroxide by hydro thermal method or at room temperature; and regulating the particle size of the synthesized double-layered hydroxide, wherein the divalent metal is magnesium, calcium or zinc, and the trivalent metal is aluminum or iron; and the base solution is sodium hydroxide or ammonia.

    Abstract translation: 提供包含双层氢氧化物的可注射药物载体以通过双层氢氧化物去除血管的破坏风险,并将有效药物输送到人体内而没有毒副作用。 可注射药物载体包含无毒双层氢氧化物和药学上可接受的添加剂,其中双层氢氧化物的粒径为100-300nm; 药物是MTX(甲氨蝶呤)。 制备可注射药物载体的方法包括以下步骤:用碱溶液滴定二价或三价金属盐溶液,通过水热法或室温合成双层氢氧化物; 并调节合成的双层氢氧化物的粒度,其中二价金属是镁,钙或锌,三价金属是铝或铁; 碱溶液为氢氧化钠或氨。

    암로디핀과 층상형 규산염의 혼성체 및 그의 제조 방법
    15.
    发明公开
    암로디핀과 층상형 규산염의 혼성체 및 그의 제조 방법 无效
    具有层状硅酸盐的混合物,其易于分散在水溶液中以提高阿米膦酸的生物利用度,并且是非水解的,使得易于制备其制剂和制备方法

    公开(公告)号:KR1020050020157A

    公开(公告)日:2005-03-04

    申请号:KR1020030057890

    申请日:2003-08-21

    Applicant: (주)씨앤팜

    CPC classification number: A61K9/1635 A61K9/143 A61K47/50

    Abstract: PURPOSE: A hybrid of amlodipine with layered silicate and a preparation process thereof are provided, which hybrid is easily dispersed in aqueous solution to increase bioavailability of amlodipine, and is non-hygroscopic enabling easy manufacturing of formulation. CONSTITUTION: The hybrid of amlodipine with layered silicate is provided, wherein the amlodipine is inserted between layers of silicate; the layered silicate is selected from montmorillonite, beidellite, nontronite, hectorite, saponite, illite, celadonite, gluconite, clay and bentonite; inorganic salt or organic base is added into the hybride in order to regulate release of amlodipine; the organic base is aminoalkyl metacrylate copolymer or polyvinylacetal diethylaminoacetate; and the inorganic salt is selected from calcium salt, sodium salt, potassium salt and ammonium salt. The process for preparing the hybrid of amlodipine with layered silicate comprises the steps of: (1) dispersing the layered silicate in aqueous solution; (2) dissolving amlodipine in ethanol or water; and (3) mixing the layered silicate solution with the amlodipine solution and stirring them.

    Abstract translation: 目的:提供氨氯地平与层状硅酸盐的混合物及其制备方法,其混合物容易分散在水溶液中以提高氨氯地平的生物利用度,并且是非吸湿性的,使制剂容易制造。 构成:提供氨氯地平与层状硅酸盐的混合物,其中氨氯地平插入硅酸盐层之间; 层状硅酸盐选自蒙脱石,贝得石,脱镁石,锂蒙脱石,皂石,伊利石,青瓷,葡萄糖甙,粘土和膨润土; 将无机盐或有机碱加入到混合物中以调节氨氯地平的释放; 有机碱是氨基烷基甲基丙烯酸酯共聚物或聚乙烯醇缩二乙基氨基乙酸酯; 无机盐选自钙盐,钠盐,钾盐和铵盐。 制备氨氯地平与层状硅酸盐的混合物的方法包括以下步骤:(1)将层状硅酸盐分散在水溶液中; (2)将氨氯地平溶于乙醇或水中; 和(3)将层状硅酸盐溶液与氨氯地平溶液混合并搅拌。

    비타민 함유 무기 하이브리드 및 그의 제조방법
    16.
    发明授权
    비타민 함유 무기 하이브리드 및 그의 제조방법 有权
    비타민함유무기하이브드드및그의제조방법

    公开(公告)号:KR100443892B1

    公开(公告)日:2004-08-09

    申请号:KR1020010046774

    申请日:2001-08-02

    Applicant: (주)씨앤팜

    Abstract: PURPOSE: Provided are vitamin-inorganic hybrid which has excellent stability to heat, light and oxygen and excellent dispersibility, and sustainedly releases vitamin to maintain efficacies of vitamin for a ling time, and a preparation thereof. CONSTITUTION: The vitamin-inorganic hybrid complex is characterized by inserting vitamin or its derivative between layers of layered double metal hydroxide as an inorganic carrier by ion exchange reaction. It is represented by the formula:(M¬2+ 1-x N¬3+ x (OH)2)(A¬n-)x/n yH2O.

    Abstract translation: 用途:提供一种维生素 - 无机杂化剂,其对热,光和氧具有优异的稳定性和优异的分散性,并持续释放维生素以维持维生素的疗效,并提供一种制剂。 组成:维生素 - 无机杂化复合物的特征在于通过离子交换反应将维生素或其衍生物插入层状双金属氢氧化物层之间作为无机载体。 它由下式表示:(M 2+ 2+ 1-x N 3+ x(OH)2)(A n - n - )x / n y H 2 O.

    약물의 안정화 및 전달을 위한 혼성 물질 및 그 제조 방법
    17.
    发明公开
    약물의 안정화 및 전달을 위한 혼성 물질 및 그 제조 방법 失效
    用于稳定和输送药物和生产的混合材料

    公开(公告)号:KR1020030014182A

    公开(公告)日:2003-02-15

    申请号:KR1020020047318

    申请日:2002-08-10

    Applicant: (주)씨앤팜

    Abstract: PURPOSE: A process of preparing a hybrid material containing 3-benzoyl-α -methylbenzene acetic acid, 4-biphenyl acetic acid, minocycline, etc. is provided. Whereby, the new hybrid material is useful in stabilization and delivery of specified drugs, low in adverse effects and excellent in stability and can be used in the form of an ointment, patch, oral administration, injection or the like. CONSTITUTION: The hybrid material is prepared by coprecipitation or ion exchange reaction of: a drug selected from the group consisting of 3-benzoyl-α-methylbenzene acetic acid, 4-biphenyl acetic acid and minocycline; and a layered inorganic material selected from the group consisting of layered silicate, layered aluminosilicate, layered phosphate and layered metal oxide.

    Abstract translation: 目的:提供一种制备含3-苯甲酰基-α-甲基苯乙酸,4-联苯乙酸,米诺环素等的杂化材料的方法。 因此,新的混合材料可用于稳定和递送特定药物,不良反应低,稳定性优异,可以以软膏,贴剂,口服给药,注射等形式使用。 构成:杂化材料通过共沉淀或离子交换反应制备:选自3-苯甲酰基-α-甲基苯乙酸,4-联苯乙酸和米诺环素的药物; 以及选自层状硅酸盐,层状硅铝酸盐,层状磷酸盐和层状金属氧化物的层状无机材料。

    다공성 가교화 점토의 제조방법
    18.
    发明公开
    다공성 가교화 점토의 제조방법 失效
    多孔交联粘土的制备方法

    公开(公告)号:KR1020010084806A

    公开(公告)日:2001-09-06

    申请号:KR1020000010120

    申请日:2000-02-29

    Applicant: (주)씨앤팜

    CPC classification number: B01J20/103 B01J20/28078

    Abstract: PURPOSE: A preparation method of porous crosslinked clay is provided which is characterized in that nano-sol particles of cationic-surface reformed metallic oxide instead of cationic cluster compounds of metallic oxide in conventional method are used for ion-exchanging inorganic cations between layers of clay and crosslinking. Accordingly, the resultant crosslinked clay has much improved surface area and thermal stability. CONSTITUTION: The method comprises the steps of: preparing nano-sol particles of metallic oxide such as SiO2 or Fe2O3-SiO2; reforming the surface of particles by cationic complexing metal, Fe; ion exchanging and crosslinking by adding prepared nano-sol solution to a suspension of clay, as montmorillonite or smectite-based clay; centrifuging, washing with aid and freeze-drying crosslinked clay; calcining at 400-550deg.C. The organic surfactant or NH4F is added to improve porous characteristics in preparation of crosslinked clay which has 300-1000m2/g of surface area, 1-3nm of pore size and 500-800deg.C of thermal stability.

    Abstract translation: 目的:提供一种多孔交联粘土的制备方法,其特征在于常规方法中阳离子表面改性金属氧化物的纳米溶胶颗粒代替金属氧化物的阳离子簇化合物用于离子交换粘土层之间的无机阳离子 和交联。 因此,所得交联粘土具有大大改善的表面积和热稳定性。 构成:该方法包括以下步骤:制备金属氧化物如SiO2或Fe2O3-SiO2的纳米溶胶颗粒; 通过阳离子络合金属Fe改性颗粒表面; 通过将制备的纳米溶胶溶液添加到粘土的悬浮液中作为蒙脱石或蒙脱石粘土进行离子交换和交联; 离心,辅助洗涤和冷冻干燥交联粘土; 焙烧400-550℃。 添加有机表面活性剂或NH4F以改善交联粘土的制备中的多孔特性,其具有300-1000m 2 / g的表面积,1-3nm的孔径和500-800deg的热稳定性。

    유전자의보관및전달이가능한생-무기하이브리드복합체및그의제조방법
    19.
    发明公开
    유전자의보관및전달이가능한생-무기하이브리드복합체및그의제조방법 有权
    可携带和转运基因的生物无机混合复合物及其制造方法

    公开(公告)号:KR1020000019408A

    公开(公告)日:2000-04-06

    申请号:KR1019980037497

    申请日:1998-09-11

    Applicant: (주)씨앤팜

    CPC classification number: C12N15/1003

    Abstract: PURPOSE: The aim is to provide a bio-inorganic hybrid complex which can carry genetic materials between layers of metal layered double hydroxide by anion exchange reaction. CONSTITUTION: The invention provides the complex of formula I (M2+1-xN3+x(OH)2)(An-)x/n·yH2O, wherein M represents metal cation such as Mg¬2+, Ni¬2+, Cu¬2+ and Zn¬2+ which are alkali-earth metals or transition metals having a valence of two. N represents metal cation such as Al¬3+, Cr¬3+, Fe¬3+, V¬3+ and Ga¬3+ which are transition metal having valence of three. A represents anionic bio-compounds such NO3¬-, CO3¬2-, Cl¬-, SO4¬2-, meta late and organic acid having a valence of n. 0 0. Charge of the layer can be controlled by changing the ratio of the metal according to X. This complex is non-toxic, reversibly dissociated and stable.

    Abstract translation: 目的:提供一种可通过阴离子交换反应在金属层状双氢氧化物层之间携带遗传物质的生物 - 无机杂化复合物。 构成:本发明提供式I(M2 + 1-xN3 + x(OH)2)(An-)x / n·yH2O的络合物,其中M表示金属阳离子如Mg 2+,Ni 2+, Cu 2+和Zn 2+是碱土金属或二价过渡金属。 N表示作为三价的过渡金属的金属阳离子,例如Al 3+,Cr 3+,Fe 3+,V 3+和Ga 3+。 A表示阴离子生物化合物,例如NO 3 - ,CO 3 - ,Cl - ,SO 4 2-,间位延迟和n价的有机酸。 0 0.可以通过根据X改变金属的比例来控制层的电荷。该复合物是无毒的,可逆解离和稳定的。

    표적지향성 siRNA-층상형 무기 수산화물 나노혼성체, 그 제조방법, 및 나노혼성체를 함유하는 종양 치료용 약학 조성물
    20.
    发明授权
    표적지향성 siRNA-층상형 무기 수산화물 나노혼성체, 그 제조방법, 및 나노혼성체를 함유하는 종양 치료용 약학 조성물 有权
    活性siRNA-无机分层双氢氧化物纳米杂交体,其制备方法和包含其的用于治疗靶向肿瘤的药物组合物

    公开(公告)号:KR101118691B1

    公开(公告)日:2012-03-12

    申请号:KR1020090086644

    申请日:2009-09-14

    Applicant: (주)씨앤팜

    Abstract: 본 발명은 강력한 유전자 치료제인 siRNA (small interfering RNA)와 표적지향성 층상형 무기 수산화물과의 나노혼성체, 그 제조방법, 및 표적지향성 siRNA-층상형 무기 수산화물 나노혼성체를 함유하는 종양 치료용 약학 조성물에 관한 것이다.
    본 발명에 따른 나노혼성체는, 종양 마커와 특이적으로 결합할 수 있는 표적지향성 다작용기 리간드가 결합된 층상형 무기 수산화물과 나노혼성체를 이루고 있는 siRNA의 생체 내 안정성이 종양특이적 전달 효율을 향상시켜 비교적 낮은 농도의 투여량에서 siRNA의 종양치료 활성을 나타내므로 범용적인 표적지향성 종양치료에 널리 활용될 수 있을 것이다.
    siRNA, 층상형 무기 수산화물, 표적지향성, 나노하이브리드, 유전자 치료제

Patent Agency Ranking